Over the past decade, therapies targeting the B-cell receptor (BCR) or the anti-apoptotic protein B-cell lymphoma 2 (BCL-2) have profoundly transformed the treatment of CLL. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.